Xiaodong Wang, Ph.D.
- Founding Director of National Institute of Biological Sciences, Beijing
- Co-founder and Chairman of SAB of BeiGene
- Member of the National Academy of Sciences, USA
- Foreign member of the Chinese Academy Sciences
- HHMI Investigator
Williamson Bradford, M.D., Ph.D.
- Former SVP, Clinical Development at InterMune, the originator of Esbriet® (Pirfenidone)
- Co-founder and CMO of Indalo Therapeutics
- More than 20 years of industry experience leading innovative drug development, including executive, clinical development, board roles, and expertise in the development of therapeutics in pulmonary fibrosis
Scott Seiwert, Ph.D.
- Former SVP of Research and Technical Development and Executive Committee member of InterMune
- Co-founder and CSO of Indalo Therapeutics
- More than 20 years of extensive experience in the management of cross functional teams consisting of drug discovery, non-clinical, CMC, and early clinical development
Toby Maher, M.D., Ph.D.
- Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California
- Specializing in the management of all forms of pulmonary fibrosis
- Research interests include basic and translational research into IPF, with a major focus on biomarker discovery, early phase clinical trials, and the pre-clinical validation of putative targets and compound for the treatment of fibrosing lung disease